

WORLD HEALTH ORGANISATION CONFIRMS XARANETIDE AS PROPOSED INTERNATIONAL NONPROPRIETARY NAME FOR ARG-007

Perth, Australia; 10 JUNE 2026 - Argenica Therapeutics Limited (ASX: AGN) (“Argenica” or the “Company”), a biotechnology company developing novel therapeutics to reduce brain tissue death after stroke and other acute neurological conditions, is pleased to announce that the World Health Organisation (WHO) has confirmed the International Nonproprietary Name (INN) **xaranetide** (“**za-RAN-e-tide**”) for the Company’s lead neuroprotective drug candidate, ARG-007, with no objections noted.

Dr Liz Dallimore, Managing Director of Argenica, commented: “ *The proposal of xaranetide as the INN for ARG-007 represents an important milestone in the maturation of our lead clinical asset. Establishing a globally recognised generic name is a key step as we continue advancing ARG-007 through clinical development and engage with regulators, investigators and future commercial partners worldwide.*”

The WHO INN Programme evaluates proposed names through a formal review process before publication in the WHO List of Proposed INNs. Following a public consultation period and consideration of any objections, the proposed name reaches the status of a recommended INN which will subsequently be published in the WHO List of recommended INNs. The consultation process has now concluded for xaranetide with no objections expressed, and the publication is expected shortly.

Xaranetide will become the recognised generic name for ARG-007 across regulatory, scientific and medical communities globally. The Company will now begin to include xaranetide in various communications.

This announcement has been approved for release by the Board of Argenica.

For more information please contact: info@argenica.com.au

ABOUT ARGENICA

Argenica Therapeutics Limited (ASX: AGN) is a clinical-stage biotechnology company developing innovative neuroprotective therapeutics to improve outcomes for patients following stroke and other acute neurological injuries. The Company’s lead drug candidate, xaranetide (ARG-007), is designed to protect vulnerable brain tissue by reducing cell death and limiting secondary damage after an ischemic event. With a strong scientific foundation and a clear clinical development pathway, Argenica is focused on advancing novel treatments that have the potential to significantly improve patient recovery and transform the standard of care in acute neurology.